Unlearn.AI creates digital twins of patients using artificial intelligence, which are virtual replicas that simulate potential health outcomes. This technology allows healthcare providers to predict how a patient's health may change over time, leading to more informed treatment decisions. The primary clients include healthcare providers and pharmaceutical companies, who can use these digital twins in clinical trials to simulate control groups, potentially speeding up drug development and approval processes. Unlearn.AI differentiates itself by offering a unique solution in the digital health market, focusing on AI-driven simulations that reduce the need for actual human control groups. The company's goal is to enhance decision-making in patient care and drug development through precise health outcome predictions.

DCVC

Insight Partners

Radical Ventures

Mubadala Capital

Wittington Ventures

EPIC Ventures

Eisai

Alumni Ventures

DCVC Bio

Necessary Ventures

Altimeter Capital

AI & Machine Learning

Healthcare

Unlearn AI

DELRAY BEACH, Fla., Dec. 17, 2024 /PRNewswire/ -- The global artificial intelligence in clinical trials market is forecasted to grow steadily from US$1.20 billion in 2023 to US$1.35 billion in 2024, ultimately reaching an impressive US$2.74 billion by 2030, driven by a robust CAGR of 12.4%. Some of the key elements fueling the expansion of the AI in clinical trials market, are the high rate of clinical trial failures, the increasing need of anticipating drug pharmacokinetics, pharmacodynamics, and management of toxicity. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The reasons that may result in failure include but not limited to effectiveness in a clinical setting, high levels of toxicity that cannot be managed, suboptimal drug-like characteristics, a lack of real commercial drivers, and poor strategic design

Artificial Intelligence In Clinical Trials Market To Hit Us$ 2.74 Billion By 2030 With 12.4% Cagr | Marketsandmarkets™.

Clinical-stage biotechnology company ProJenX has announced a collaboration with Unlearn to implement generative AI technology for a Phase I PRO-101 trial of prosetin, a potential amyotrophic lateral sclerosis (ALS) treatment.

ProJenX and Unlearn partner to use AI-generated digital twins in ALS trial

To deal with the difficulty of conducting these clinical trials, Eisai invested in Unlearn.AI, Inc. ("Unlearn") in 2020.

Litigating Trade Secrets in Biotech, Life Sciences, and AI: The High-Stakes Battle Over Clinical Trial Innovations

Artificial intelligence (AI) is transforming industries and revolutionizing the way we live and work. As AI technology continues to advance at a rapid pace, startups are at the forefront of driving innovation and developing groundbreaking solutions. From advanced language models and image generation to automated machine learning and collaborative data science platforms, these startups are pushing the boundaries of what’s possible with AI. Here are 25 groundbreaking startups shaping the future of AI:1. BriefBrief is a news curation and summarization platform that uses AI to provide a more efficient way for people to stay informed on topics they care about. It curates and summarizes news articles into concise, easy-to-digest summaries, covering over 25 diverse topics.2

25 Groundbreaking Startups Shaping The Future Of Ai

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, a leader in artificial intelligence research in medicine, today announced the appointment of Steve Herne as its first Chief Commercial Officer. Herne will spearhead commercial strategies to propel the company’s growth following their successful Series C funding. "Things continue to move fast at Unlearn, and Steve’s proven track record in healthcare innovation makes him the perfect leader to shape our commercial strategy,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. Herne, with over 25 years of experience in the pharmaceutical research and development market, has previously led long-term strategic direction as Chief Commercial Officer at WCG and Bioclinica. Herne's impressive career also includes leadership positions at ERT, Icon Development Solutions, Covance, MDS Pharma Services, and Inveresk Research

Steven Herne Joins Unlearn’S Executive Team As Chief Commercial Officer

DUBLIN, March 29, 2024 /PRNewswire/ -- The "Global AI-based Clinical Trials Solution Provider Market Analysis & Forecast to 2024-2034: Market By Clinical Trial Phase; By Therapeutic Application; By End-user; and By Region" report has been added to ResearchAndMarkets.com's offering.The global AI-based clinical trials solution provider market size was estimated to be USD 2 billion in 2023 and is expected to reach at USD 17.95 billion by 2034 with a CAGR of 22.08% during the forecast period 2024-2034.Growing adoption of AI-based platforms to enhance the productivity and efficiency of trials across different stages, surge in supportive initiatives from both private & public sectors, spanning various therapeutic areas, rising awareness of AI's diverse applications in clinical trials, growing implementation of AI-based technologies, increasing penetration of AI in drug trials, the availability of AI-based solutions, surge in adoption of technologically advanced solutions for drug discovery, development, & the analysis of recruited patient data, an upswing in research & development activities, rising introduction of cutting-edge AI-based clinical trial platforms are some of the pivotal elements contributing to the expansion of the market.Rising introduction of cutting-edge AI-based clinical trial platforms is predicted to boost the market growth during the forecast period. Artificial intelligence has the potential to identify diseases, offer healthcare services, and contribute to the development of novel treatments. Its application in drug trials proves beneficial for enhancing the cost-effectiveness, clinical outcomes, and time efficiency of the drug development process, known for its resource-intensive nature. Pharmaceutical companies, Contract Research Organizations (CROs), and academic institutions have redirected their attention from the conventional drug development approach towards AI-based solutions. This shift aims to optimize clinical outcomes while minimizing both the cost and time associated with drug trials. For instance, in September 2023, Belong.Life has introduced Tara, a Software-as-a-Service (SaaS) conversational AI platform for matching cancer patients with clinical trials, targeting health providers and contract research organizations (CROs)

Ai-Based Clinical Trials Solution Provider Market Report 2024-2034, Featuring Consilx, Aicure, Unlearn.Ai, Trials.Ai, Intelligencia, Symphony Ai, Gns Healthcare, Verily, Biosymetrics  Bioage Labs

Technology company Unlearn has introduced the latest version of its TwinRCT solution, TwinRCT 3.0, to enhance decision-making in Phase II clinical trials.

Unlearn launches TwinRCT 3.0 to enhance Phase II trials

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, a company at the forefront of AI in medicine, today announced the newest version of its TwinRCT™ solution, TwinRCT 3.0. TwinRCTs are randomized clinical trials that use digital twins of trial participants—comprehensive forecasts of individual clinical outcomes—to optimize clinical trials. Participants’ digital twins are generated by AI models trained on patient-level data, and they enable trials with higher power or smaller control arms. Unlearn’s updated TwinRCT can now incorporate additional previous clinical trial data to provide an even more robust framework for Phase 2 trial evaluations, which represent a crucial stage in the drug development process. Phase 2 trials serve as a litmus test for a new drug's effectiveness. The more highly powered a trial is at this stage, the more likely a treatment effect can be detected—determining whether or not the trial will advance to the more resource-intensive Phase 3 stage

Unlearn’S Twinrct Solution Update Enhances Phase 2 Trial Decision-Making Power

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, a company at the forefront of AI in the clinical trial space, today announced the launch of TrialPioneer. This web-based application is free for teams in pharmaceutical and biotech companies to collaborate and understand how trial design choices affect the sample size requirements, statistical power, and time to enrollment—initially in seven major disease areas (Alzheimer’s Disease, ALS, Crohn’s Disease, Frontotemporal Dementia, Huntington’s Disease, Parkinson's Disease, and Ischemic Stroke). It also reveals the major advantages that novel AI-powered trial designs offer over traditional approaches. TrialPioneer is designed to make clinical trial planning more efficient for professionals, including medical directors, clinicians, and statisticians. Users can evaluate clinical trials by utilizing Unlearn's analysis of its extensive datasets from actual patient populations in completed trials. The tool addresses the impact of design decisions (primary endpoint, treatment duration, patient subpopulation, etc.) on the required sample size and/or power

Introducing Unlearn’S Trialpioneer: A Free Tool For Exploring Innovative Clinical Trial Designs Using Ai

Unlearn.ai has filed a notice of an exempt offering of securities to raise $49,999,956.00 in New Equity Investment. Unlearn.ai has filed a notice of an exempt offering of securities to raise $49,999,956.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, Unlearn.ai is raising up to $49,999,956.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Charles Fisher played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About Unlearn.aiEnrollment challenges and timeline delays plague clinical trials. External controls can help solve these problems, but are typically unreliable. TwinRCTs generate reliable evidence in a fraction of the time

Unlearn.Ai Has Filed A Notice Of An Exempt Offering Of Securities To Raise $49,999,956.00 In New Equity Investment.

Creates AI-driven digital twins for healthcare

Unlearn AI

Creates AI-driven digital twins for healthcare

Unlearn AI

Creates AI-driven digital twins for healthcare

About

Simplify's Take

What believers are saying

What critics are saying

What makes Unlearn AI unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Unlearn AI is Hiring for 0 Jobs on Simplify!